Prosecution Insights
Prosecution Insights
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §102 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 45.8% | +21.5% |
| DENT, ALANA HARRIS | 1 | 44.6% | +32.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18021677 | Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment | BUTTICE, AUDREY L | 16d overdue |
| 18041723 | HUMANIZED ANTIBODY, CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID, VECTOR, CELL AND USE | DENT, ALANA HARRIS | 72d |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18021677 | Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment | BUTTICE, AUDREY L | 1647 | §103 | Final Rejection | 16d overdue | Pending | Feb 16, 2023 |
| 18041723 | HUMANIZED ANTIBODY, CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID, VECTOR, CELL AND USE | DENT, ALANA HARRIS | 1643 | §102 | Non-Final OA | 72d | Pending | Feb 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial